Log in to search using one of your social media accounts:

This page shows you the latest clinical trials in this category.

Characterization of Non-Steroidal Anti-Inflammatory Drug (NSAID) Intake in Rheumatoid Arthritis (RA) Participants on Tocilizumab (RoACTEMRA ®) Treatment
Condition:   Rheumatoid Arthritis Interventions:   Drug: Tocilizumab;   Drug: NSAIDs Sponsor:   Hoffmann-La Roche Recruiting - verified April 2017 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 10, 2017 Category: Research Source Type: clinical trials

Head-to-head comparison of aggressive conventional therapy and three biological treatments and comparison of two de-escalation strategies in patients who respond to treatment: study protocol for a multicenter, randomized, open-label, blinded-assessor, phase 4 study
DiscussionNORD-STAR is the first investigator-initiated, randomized, early RA trial to compare (1) csDMARD and three different bDMARD therapies head to head and (2) two different de-escalation strategies. The trial has the potential to identify which treatment strategy to apply in early RA to achieve the best possible outcomes for both patients and society.Trial registrationNCT01491815 andNCT02466581. Registered on 8 December 2011 and May 2015, respectively.EudraCT: 2011-004720-35 (Source: Trials)
Source: Trials - April 4, 2017 Category: Research Source Type: clinical trials

Observational Study to Assess the Safety of FURESTEM-RA Lnj. In Patients With Moderate to Severe Rheumatoid Arthritis
Condition:   Rheumatoid Arthritis Intervention:   Drug: FURESTEM-RA Inj. Sponsor:   Kang Stem Biotech Co., Ltd. Active, not recruiting - verified April 2017 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 3, 2017 Category: Research Source Type: clinical trials

Evaluation of the Impact of 3 Methods of Communication on the Adherence of Methotrexate in Patients With Rheumatoid Arthritis
Conditions:   Methotrexate;   Polyarthritis; Rheumatoid Intervention:   Other: Communication methods to encourage adherence Sponsor:   Centre Hospitalier Universitaire, Amiens Recruiting - verified April 2017 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 31, 2017 Category: Research Source Type: clinical trials

A Phase 3 Study to Compare ABT-494 to Abatacept in Subjects With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response or Intolerance to Biologic DMARDs
Condition:   Rheumatoid Arthritis Interventions:   Drug: ABT-494;   Drug: Abatacept;   Drug: ABT-494 matching placebo;   Drug: Abatacept matching placebo Sponsor:   AbbVie Not yet recruiting - verified March 2017 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 22, 2017 Category: Research Source Type: clinical trials

Rheumatoid Arthritis Treatment After First Anti-TNF INvestiGation
Condition:   Rheumatoid Arthritis Interventions:   Drug: Tocilizumab;   Drug: Etanercept;   Drug: Infliximab;   Drug: Adalimumab;   Drug: Golimumab;   Drug: Certolizumab Pegol Sponsor:   Mario Negri Institute for Pharmacological Research Not yet recruiting - verified March 2017 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 17, 2017 Category: Research Source Type: clinical trials

Dental Prophylaxis and Rheumatoid Arthritis
Conditions:   Rheumatoid Arthritis;   Periodontitis;   Gingivitis;   Dental Prophylaxis Intervention:   Procedure: Dental Prophylaxis Sponsor:   University Hospital Heidelberg Recruiting - verified March 2017 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 15, 2017 Category: Research Source Type: clinical trials